Bioventus (BVS) CFO receives major stock awards and exercises RSUs

Rhea-AI Filing Summary

Bioventus Inc. SVP & CFO Mark Leonard Singleton reported multiple equity compensation transactions in company stock. He received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share, both granted on March 13, 2026. He also reported earlier grants from March 14, 2025 of 54,000 RSUs and a stock option for 61,000 shares at $9.6100 per share. On the same 2026 date, he exercised 13,500 RSUs into 13,500 shares of Class A common stock, with 5,865 shares withheld to cover tax obligations. After these transactions, he directly holds 159,447 shares of Class A common stock. The RSUs and options vest in four equal annual installments starting on March 15, 2025 and March 15, 2026, subject to his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singleton Mark Leonard

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/13/2026		M		13,500	A	$0	165,312	D
Class A Common Stock	03/13/2026		F		5,865	D	$8.62	159,447	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/14/2025		A		54,000		(2)	(2)	Class A Common Stock	54,000	$0	54,000	D
Stock Option (Right to Buy)	$9.61	03/14/2025		A		61,000		(2)	03/14/2035	Class A Common Stock	61,000	$0	61,000	D
Restricted Stock Units	(1)	03/13/2026		A		104,000		(3)	(3)	Class A Common Stock	104,000	$0	104,000	D
Stock Option (Right to Buy)	$8.62	03/13/2026		A		116,000		(3)	03/13/2036	Class A Common Stock	116,000	$0	116,000	D
Restricted Stock Units	(1)	03/13/2026		M			13,500	(2)	(2)	Class A Common Stock	13,500	$0	40,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

3. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Bioventus (BVS) CFO Mark Singleton receive in March 2026?

Mark Singleton received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share. These equity awards form part of his long-term incentive compensation.

Did the Bioventus (BVS) CFO sell any shares in this Form 4 filing?

The filing shows no open-market sales by the CFO. Instead, 5,865 shares of Class A common stock were withheld at $8.6200 per share to cover tax obligations related to a restricted stock unit vesting and exercise event.

How many Bioventus (BVS) shares does the CFO hold after these transactions?

Following the reported equity awards, RSU exercise, and tax withholding, Mark Singleton directly holds 159,447 shares of Bioventus Class A common stock. This figure reflects his post-transaction ownership as disclosed in the Form 4 filing.

What were the earlier Bioventus (BVS) equity grants reported from March 2025?

The Form 4 also reports prior grants dated March 14, 2025, of 54,000 restricted stock units and a stock option for 61,000 shares of Class A common stock, with an exercise price of $9.6100 per share, as part of the CFO’s compensation.

How do the Bioventus (BVS) CFO’s RSUs and options vest over time?

The restricted stock units and options vest in four equal installments on each of the first four anniversaries of March 15, 2025 and March 15, 2026. Vesting is conditioned on the CFO continuing in service through each applicable vesting date.

What derivative exercise is disclosed for the Bioventus (BVS) CFO?

The filing shows an exercise of 13,500 restricted stock units into 13,500 shares of Class A common stock. In connection with this event, 5,865 shares were withheld to satisfy tax liabilities, rather than being sold on the open market.